Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

By
May Ee Png
Victoria Harris
Ly-Mee Yu
Paul Little
F. D. Richard Hobbs
Christopher C. Butler
Stavros Petrou
PANORAMIC Trial Collaborative Group
Oghenekome A Gbinigie
Najib M Rahman
Gail Hayward
Duncan B Richards
Jienchi Dorward
David M Lowe
Joseph F Standing
Judith Breuer
Saye Khoo
Kerenza Hood
Jonathan S Nguyen-Van-Tam
Mahendra G Patel
Benjamin R Saville
Joe Marion
Nick Francis
Nicholas P B Thomas
Philip Evans
Melissa Dobson
Jane Holmes
Mark Lown
Oliver van Hecke
Michelle A Detry
Christina T Saunders
Mark Fitzgerald
Nicholas S Berry
Sam Mort
Bhautesh D Jani
Nigel D Hart
Haroon Ahmed
Daniel Butler
Micheal McKenna
Lucy Cureton
Meena Patil
Monique Andersson
Clare Bateman
Jennifer C Davies
Andrew Ustianowski
Andrew Carson Stevens
May 6, 2026
0 min

Jama Network Open

Overview

This report evaluates the cost-effectiveness of nirmatrelvir-ritonavir for high-risk COVID-19 outpatients, demonstrating significant reductions in hospitalization and death. The analysis leverages data from a randomized clinical trial to provide robust economic insights.

Background

Nirmatrelvir-ritonavir has been recognized for its efficacy in reducing severe outcomes in high-risk COVID-19 patients. Its cost-effectiveness is crucial for healthcare systems, especially during the Omicron wave, where targeted treatment can mitigate healthcare burdens. Understanding its economic implications helps inform treatment guidelines and resource allocation.

Data Highlights

This economic evaluation was conducted alongside the PANORAMIC trial, comparing nirmatrelvir-ritonavir with usual care over a 6-month period under the UK NHS perspective.

Key Findings

Nirmatrelvir-ritonavir reduced the risk of hospitalization or death by 89% when initiated within 5 days of symptom onset.
Cost-effectiveness varied by vaccination status, with some studies indicating it was primarily effective for unvaccinated high-risk individuals.
The economic evaluation followed NICE reference case requirements, ensuring relevance for decision-makers.
Data were collected from multiple UK health databases, enhancing the robustness of the findings.
Prior evaluations were nonrandomized, highlighting the strength of this trial-based approach.

Clinical Implications

Healthcare providers should consider nirmatrelvir-ritonavir as a first-line treatment for high-risk COVID-19 patients, particularly those unvaccinated or with comorbidities. The findings underscore the importance of timely intervention within 5 days of symptom onset to maximize treatment benefits.

Conclusion

The trial-based economic evaluation of nirmatrelvir-ritonavir provides compelling evidence for its cost-effectiveness in high-risk COVID-19 patients, supporting its continued use in clinical practice.